Health Trials

A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis

ConditionTakayasu Arteritis
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorShanghai Zhongshan Hospital

About this trial

This study aimed to compare the efficacy and safety of a precision treatment regimen based on clinical-molecular phenotypes with a conventional treatment regimen in the treatment of patients with active Takayasu's arteritis based on a randomized, controlled, open-label, multicenter study.

Eligibility criteria

Qualifiers

None

Disqualifiers

Presence of organ failure;

undergoing haemodialysis or major surgery (grade III and above) within 3 months;

the presence of other autoimmune diseases;

severe, progressive organ damage;

Trial design

Treatments tested in this trial

  • Prednisone
  • Methotrexate
  • Tocilizumab
  • Tofacitinib
  • Adalimumab

Treatment groups

124 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Shanghai Zhongshan Hospital

Lead sponsor

Source ClinicalTrials.gov